What are the main challenges of CAR T in AML compared to lymphoma and multiple myeloma?

During the 2nd European CAR T Cell Meeting in Sitges, ES, the AML Global Portal was delighted to speak to Mohamad Mohty, Saint-Antoine Hospital and Sorbonne University, Paris, FR. We asked: What are the main challenges of CAR T in AML compared to lymphoma and multiple myeloma?

Mohamad Mohty explains in lymphoma and multiple myeloma there has been an identification of disease-specific antigens such as CD19 and BCMA, that avoids the targeting of healthy tissue and therefore has allowed the generation of effective CAR T cells constructs. He explains that the challenge with CAR T in AML is due to no such antigens have been identified.